FHI successfully registers Sino-implant (II) in Kenya

28th August 2008

Coalition member Family Health International (FHI) is pleased to announce that Pharm Access Africa Limited (PAAL) successfully registered Sino-implant (II), a subdermal contraceptive implant, in Kenya on August 27, 2008. The implants are manufactured by Shanghai Dahua Pharmaceutical Co. Ltd. and will be marketed in Kenya under the trade name Zarin.

Sino-implant (II) has been in widespread use in China and Indonesia for 15 years. Its registration in Kenya is the first in a series of submissions-coordinated by FHI-to drug regulatory authorities across Africa. Representatives from FHI´s Nairobi office will be discussing the introduction of Zarin with officials at Kenya´s Division of Reproductive Health (DRH) in the near future. FHI also expects to meet with family planning stakeholders during the DRH´s family planning meeting in November.

Based on research conducted by FHI (Hubacher, Contraception 2007), the current infrastructure can be used to successfully scale-up of Zarin in Kenya. FHI looks forward to working with its service delivery partners in a well-coordinated introduction of Zarin. 

Click here to read more about Sino-Implant (II).

Categories: Featured, Market Development Approaches Working Group

You are currently offline. Some pages or content may fail to load.